03/15/23 4:10 PMNasdaq : AURA earningsclinical triallow floatAura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational HighlightsAura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the fourth quarter and year ended December 31, 2022, and provided clinical development and operational highlights. Cadmus Rich, Chief Medical Officer of...RHEA-AIvery positive
02/16/23 7:00 AMNasdaq : AURA clinical triallow floatAura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal AdministrationAura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the presentation of positive interim Phase 2 safety and efficacy data of bel-sar with 9-10 months of follow up evaluating two key clinical endpoints: tumor control and visual...RHEA-AIneutral
02/09/23 7:00 AMNasdaq : AURA conferenceslow floatAura Biosciences to Participate in Upcoming Investor ConferencesAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:. SVB Securities Global Biopharma Conference on...RHEA-AIneutral
11/30/22 8:50 PMNasdaq : AURA offeringlow floatAura Biosciences Announces Pricing of Public Offering of Common StockAura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 6,700,000 shares of its common stock at a price to the public of $12.00 per share. A shelf registration statement relating to...RHEA-AIneutral
11/30/22 4:01 PMNasdaq : AURA offeringlow floatAura Biosciences Announces Proposed Public Offering of Common StockAura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the launch of an underwritten public offering of its common stock. A shelf registration statement relating to the shares of common stock offered in the public offering...RHEA-AIneutral
11/10/22 7:00 AMNasdaq : AURA earningsclinical triallow floatAura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational HighlightsAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2022 and provided clinical development and operational highlights. “We are encouraged by the meaningful clinical...RHEA-AIneutral
11/10/22 6:45 AMNasdaq : AURA clinical triallow floatAura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal MelanomaAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that it has initiated startup activities for the global Phase 3 trial. Cadmus Rich, Chief Medical Officer of Aura Biosciences.“ We are pleased to have aligned with regulatory...RHEA-AIvery positive
11/03/22 7:00 AMNasdaq : AURA conferenceslow floatAura Biosciences to Participate in Upcoming Investor ConferencesAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that members of its executive team will participate in the following upcoming investor conferences:. Stifel 2022 Healthcare Conference at the Lotte New York Palace on...RHEA-AIneutral
10/03/22 7:00 AMNasdaq : AURA clinical triallow floatAura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that interim Phase 2 data evaluating the safety and efficacy of suprachoroidal administration using its first VDC product candidate, belzupacap sarotalocan, for the...RHEA-AIneutral
09/28/22 7:00 AMNasdaq : AURA clinical triallow floatAura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder CancerAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the first patient has been dosed in a Phase 1 study evaluating belzupacap sarotalocan, the Company’ s first VDC product candidate, for the treatment of Non-Muscle Invasive...RHEA-AIneutral